These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 21846718)

  • 1. Orientation and cellular distribution of membrane-bound catechol-O-methyltransferase in cortical neurons: implications for drug development.
    Chen J; Song J; Yuan P; Tian Q; Ji Y; Ren-Patterson R; Liu G; Sei Y; Weinberger DR
    J Biol Chem; 2011 Oct; 286(40):34752-60. PubMed ID: 21846718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of non-nitrocatechol pan and isoform specific catechol-O-methyltransferase inhibitors and substrates.
    Robinson RG; Smith SM; Wolkenberg SE; Kandebo M; Yao L; Gibson CR; Harrison ST; Polsky-Fisher S; Barrow JC; Manley PJ; Mulhearn JJ; Nanda KK; Schubert JW; Trotter BW; Zhao Z; Sanders JM; Smith RF; McLoughlin D; Sharma S; Hall DL; Walker TL; Kershner JL; Bhandari N; Hutson PH; Sachs NA
    ACS Chem Neurosci; 2012 Feb; 3(2):129-40. PubMed ID: 22860182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice.
    Detrait ER; Carr GV; Weinberger DR; Lamberty Y
    Behav Pharmacol; 2016 Aug; 27(5):415-21. PubMed ID: 26919286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats.
    Huotari M; Passlin M; Nordberg HL; Forsberg M; Kotisaari S; Tuomisto L; Shintani F; Tanaka KF; Reenilä I; Laitinen K; Männistö PT
    J Neurosci Methods; 2001 Aug; 109(1):47-52. PubMed ID: 11489299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase.
    Vieira-Coelho MA; Soares-da-Silva P
    Brain Res; 1999 Mar; 821(1):69-78. PubMed ID: 10064789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase.
    Borges N; Vieira-Coelho MA; Parada A; Soares-da-Silva P
    J Pharmacol Exp Ther; 1997 Aug; 282(2):812-7. PubMed ID: 9262345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of hippocampal dopamine metabolism and hippocampal-dependent cognitive function by catechol-O-methyltransferase inhibition.
    Laatikainen LM; Sharp T; Bannerman DM; Harrison PJ; Tunbridge EM
    J Psychopharmacol; 2012 Dec; 26(12):1561-8. PubMed ID: 22815336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
    Napolitano A; Bellini G; Borroni E; Zürcher G; Bonuccelli U
    Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism.
    Giakoumaki SG; Roussos P; Bitsios P
    Neuropsychopharmacology; 2008 Dec; 33(13):3058-68. PubMed ID: 18536698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of catechol-O-methyl transferase (COMT) by tolcapone restores reductions in microtubule-associated protein 2 (MAP2) and synaptophysin (SYP) following exposure of neuronal cells to neurotropic HIV.
    Lee TT; Chana G; Gorry PR; Ellett A; Bousman CA; Churchill MJ; Gray LR; Everall IP
    J Neurovirol; 2015 Oct; 21(5):535-43. PubMed ID: 26037113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sexually dimorphic effects of catechol-O-methyltransferase (COMT) inhibition on dopamine metabolism in multiple brain regions.
    Laatikainen LM; Sharp T; Harrison PJ; Tunbridge EM
    PLoS One; 2013; 8(4):e61839. PubMed ID: 23613951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotype-Dependent Effects of COMT Inhibition on Cognitive Function in a Highly Specific, Novel Mouse Model of Altered COMT Activity.
    Barkus C; Korn C; Stumpenhorst K; Laatikainen LM; Ballard D; Lee S; Sharp T; Harrison PJ; Bannerman DM; Weinberger DR; Chen J; Tunbridge EM
    Neuropsychopharmacology; 2016 Dec; 41(13):3060-3069. PubMed ID: 27388330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition.
    Farrell SM; Tunbridge EM; Braeutigam S; Harrison PJ
    Biol Psychiatry; 2012 Mar; 71(6):538-44. PubMed ID: 22364739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolcapone improves cognition and cortical information processing in normal human subjects.
    Apud JA; Mattay V; Chen J; Kolachana BS; Callicott JH; Rasetti R; Alce G; Iudicello JE; Akbar N; Egan MF; Goldberg TE; Weinberger DR
    Neuropsychopharmacology; 2007 May; 32(5):1011-20. PubMed ID: 17063156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Membrane bound catechol-O-methytransferase is the dominant isoform for dopamine metabolism in PC12 cells and rat brain.
    Su Y; DePasquale M; Liao G; Buchler I; Zhang G; Byers S; Carr GV; Barrow J; Wei H
    Eur J Pharmacol; 2021 Apr; 896():173909. PubMed ID: 33503461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The disposition of the tolcapone 3-O-methylated metabolite is affected by the route of administration in rats.
    Funaki T; Onodera H; Ushiyama N; Tsukamoto Y; Tagami C; Fukazawa H; Kuruma I
    J Pharm Pharmacol; 1994 Jul; 46(7):571-4. PubMed ID: 7996385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma.
    Maser T; Rich M; Hayes D; Zhao P; Nagulapally AB; Bond J; Saulnier Sholler G
    Cancer Med; 2017 Jun; 6(6):1341-1352. PubMed ID: 28429453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Comt with tolcapone slows progression of polycystic kidney disease in the more severely affected PKD/Mhm (cy/+) substrain of the Hannover Sprague-Dawley rat.
    Boehn SN; Spahn S; Neudecker S; Keppler A; Bihoreau MT; Kränzlin B; Pandey P; Hoffmann SC; Li L; Torres VE; Gröne HJ; Gretz N
    Nephrol Dial Transplant; 2013 Aug; 28(8):2045-58. PubMed ID: 23543593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opposite effects of tolcapone on amphetamine-disrupted startle gating in low vs. high COMT-expressing rat strains.
    Swerdlow NR; Hines SR; Herrera SD; Weber M; Breier MR
    Pharmacol Biochem Behav; 2013 May; 106():128-31. PubMed ID: 23567203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme.
    Lotta T; Vidgren J; Tilgmann C; Ulmanen I; Melén K; Julkunen I; Taskinen J
    Biochemistry; 1995 Apr; 34(13):4202-10. PubMed ID: 7703232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.